Biotech seed rounds sink to lowest level in years as industry slump drags on
Port Therapeutics, a nimble biotech with well-known academic and executive names, went to more than 100 investors last year to move beyond the seed stage …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
